Showing 2781-2790 of 5956 results for "".
- Multifocal Contact Lenses With High Add Power Help Slow Myopia Progressionhttps://modernod.com/news/multifocal-contact-lenses-with-high-add-power-help-slow-myopia-progression/2478162/Soft multifocal contact lenses with a high add power help slow progression of myopia in children, more so than multifocal lenses with medium add power or single-vision lenses, according to results of the BLINK trial, Reuters reported.
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- Health Canada Approves Bausch + Lomb Ultra One Day Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/health-canada-approves-bausch-lomb-ultra-one-day-silicone-hydrogel-daily-disposable-contact-lenses/2478142/Bausch + Lomb announced that it has received approval from Health Canada for the sale of Bausch + Lomb Ultra One Day daily disposable silicone hydrogel (SiHy daily) contact lenses. Bausch + Lomb Ultra One Day contact lenses feature a next generation contact lens material (kalifilcon A) wit
- Eyenovia and Arctic Vision Announce License Agreement to Develop and Commercialize Products in Greater China and South Koreahttps://modernod.com/news/eyenovia-and-arctic-vision-announce-license-agreement-to-develop-and-commercialize-products-in-greater-china-and-south-korea/2478143/Eyenovia and Arctic Vision announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Tai
- At Least 97,000 Children Tested Positive For Coronavirus In Last 2 Weeks Of Julyhttps://modernod.com/news/at-least-97000-children-tested-positive-for-coronavirus-in-last-2-weeks-of-july-at-least-97000-children-tested-positive-for-the-coronavirus-during-the-last-two-weeks-of-july-according-to-a-new-revi/2478145/At least 97,000 children tested positive for the coronavirus during the last two weeks of July, according to a new review of state-level data by the Americ
- AstraZeneca Takes COVID-19 Vaccine to China With BioKangtai Deal for 200M-Dose Capacity by 2021https://modernod.com/news/astrazeneca-takes-covid-19-vaccine-to-china-with-biokangtai-deal-for-200m-dose-capacity-by-2021/2478134/Last week China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That has changed, according to a FiercePharma
- Bausch + Lomb Launches -2.75 Cylinder for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-2-75-cylinder-for-biotrue-oneday-for-astigmatism-daily-disposable-contact-lenses/2478129/Bausch + Lomb announced the US launch of the -2.75 cylinder parameter offering for Biotrue ONEday for Astigmatism daily disposable contact lenses, the first and only toric daily disposable with a -2.75 cylinder. This new parameter offering will be available for same day fitting in a standard fit
- EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-and-imprimisrx-announce-u-s-commercial-alliance-for-dexycu/2478119/EyePoint Pharmaceuticals and ImprimisRx announced the signing of a commercial alliance for the joint promotion of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in the United States.
- Sanofi, GSK Gain $2.1 Billion From US Government for Development, Supply of COVID-19 Vaccinehttps://modernod.com/news/sanofi-gsk-gain-2-1-billion-from-us-government-for-development-supply-of-covid-19-vaccine/2478107/Sanofi and GlaxoSmithKline announced that the US government will provide more than $2.1 billion to support further development, manufacturing and delivery of initial doses of the companies’ adjuvanted vaccine against COVID-19. The vaccine candidate is based on Sanofi’s recombinant pro
- Kubota Vision Demonstrates 3D Imaging Capabilities Using AI on PBOShttps://modernod.com/news/kubota-vision-demonstrates-3d-imaging-capabilities-using-ai-on-pbos/2478095/Kubota Vision announced that the company demonstrated 3D imaging capabilities using artificial intelligence (AI) on its Patient Based Ophthalmology Suite (PBOS) in-home optical coherence tomography (OCT) device.1 Kubota Vision completed a successful clinical study in October 201